Idiopathic Generalized Epilepsy Syndromes
Condition(s) studied
Study summary
The idiopathic generalized epilepsies (IGEs) have historically included the syndromes childhood absence epilepsy (CAE), juvenile absence epilepsy (JAE), juvenile myoclonic epilepsy (JME), and epilepsy with generalized tonic-clonic seizures alone (GTCA). Recognition of the IGEs is important for clinical care, as it informs diagnosis, prevents unnecessary investigation, allows optimal selection of anti-seizure medications (ASMs), and provides prognostic guidance.
According to the new ILAE definition in 2022, the study aims to describe the clinical features, electroencephalographic, imaging findings and long-term prognosis.
Eligibility
Primary outcome measure(s)
- The proportion of drug-resistent epilepsy — through study completion, an average of 1 year
We defined drug-resistant cases as those patients who have failed two or more trials of broad-spectrum ASMs or those otherwise indicated in IGE syndromes - The proportion of seizure freedom — through study completion, an average of 1 year
We defined seizure freedom according to the International League Against Epilepsy (ILAE) definition
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China | Hangzhou | Zhejiang | Recruiting |
More Shen Chun-Hong trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06388174 on ClinicalTrials.gov ↗ ← All trials in China